Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Open access
Raskov, Hans, Orhan, Adile, Christensen, Jan Pravsgaard, Gögenur, Ismail · 2021 · British Journal of Cancer

Abstract

The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8 + T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8 + T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-020-01048-4

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 T-cell differentiation—an overview. Common lymphoid progenitor cells giving rise to immature precursor T cells originate in the red bone marrow. Due to the production in the thymus of chemotactic agents/thymic factors (e.g., thymotaxin, thymosin and thymopoietin), immature precursor T cells (being TCR- and CD-negative [double negative]) enter the circulation and are directed to the thymus. Within the thymus, the same agents induce the production of TCR and CD proteins. Thymic cells present the now CD- and TCR-positive T cells for MHC-1 and MHC-2 molecules to identify T-cell reactivity and direct their maturation pathways. During the positive selection process, T cells being able to bind MHC class I or II molecules with at least a weak affinity are identified. By negative selection, T cells with a high affinity for self-peptides undergo apoptosis to minimise the risk of immune responses towards self-proteins in the periphery. T cells with TCR affinity for MHC-1 become CD8+ T cells and T cells with TCR affinity for MHC-2 become CD4+ T cells. Depending on cytokine and stromal cell signalling, they may also differentiate into T-helper and T-regulatory cells. MHC: major histocompatibility complex.
Fig. 1 T-cell differentiation—an overview. Common lymphoid progenitor cells giving rise to immature precursor T cells originate in the red bone marrow. Due to the production in the thymus of chemotactic agents/thymic factors (e.g., thymotaxin, thymosin and thymopoietin), immature precursor T cells (being TCR- and CD-negative [double negative]) enter the circulation and are directed to the thymus. Within the thymus, the same agents induce the production of TCR and CD proteins. Thymic cells present the now CD- and TCR-positive T cells for MHC-1 and MHC-2 molecules to identify T-cell reactivity and direct their maturation pathways. During the positive selection process, T cells being able to bind MHC class I or II molecules with at least a weak affinity are identified. By negative selection, T cells with a high affinity for self-peptides undergo apoptosis to minimise the risk of immune responses towards self-proteins in the periphery. T cells with TCR affinity for MHC-1 become CD8+ T cells and T cells with TCR affinity for MHC-2 become CD4+ T cells. Depending on cytokine and stromal cell signalling, they may also differentiate into T-helper and T-regulatory cells. MHC: major histocompatibility complex.CC BY · PubMed Central
Fig. 2 T-cell activation: the T-cell receptor (TCR) complex. Extracellularly, the TCR consists of the α and β chains, both of which have a constant region (C) and variable region (V), with the latter determining antigen specificity. The TCRαβ antigen-binding subunit is non-covalently bound to three CD3 co-receptor signalling subunits (ζζ, CD3δε and CD3γε), all of which contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domains. SS disulfide bridge.
Fig. 2 T-cell activation: the T-cell receptor (TCR) complex. Extracellularly, the TCR consists of the α and β chains, both of which have a constant region (C) and variable region (V), with the latter determining antigen specificity. The TCRαβ antigen-binding subunit is non-covalently bound to three CD3 co-receptor signalling subunits (ζζ, CD3δε and CD3γε), all of which contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domains. SS disulfide bridge.CC BY · PubMed Central
Fig. 3 T-cell activation. The V domains of the α and β chains on T cells interact with an antigenic peptide presented by MHC-1 on the target cell, while the co-receptor CD8 associates with TCR–MHC-1 to tightly secure the TCR–CD3 complex to the major histocompatibility complex (MHC)–peptide complex. As CD8 binds to the MHC-1, Lck phosphorylates the intracellular portions of the CD3 ITAMs and positions ZAP-70 to phosphorylate the transmembrane proteins that allow the CD8+ T cell to secrete its cytokines. Lck: lymphocyte-specific protein tyrosine kinase, P: phosphorylation, CD45: receptor-linked protein tyrosine phosphatase, Zap70: ζ chain of T-cell-receptor-associated protein kinase 70.
Fig. 3 T-cell activation. The V domains of the α and β chains on T cells interact with an antigenic peptide presented by MHC-1 on the target cell, while the co-receptor CD8 associates with TCR–MHC-1 to tightly secure the TCR–CD3 complex to the major histocompatibility complex (MHC)–peptide complex. As CD8 binds to the MHC-1, Lck phosphorylates the intracellular portions of the CD3 ITAMs and positions ZAP-70 to phosphorylate the transmembrane proteins that allow the CD8+ T cell to secrete its cytokines. Lck: lymphocyte-specific protein tyrosine kinase, P: phosphorylation, CD45: receptor-linked protein tyrosine phosphatase, Zap70: ζ chain of T-cell-receptor-associated protein kinase 70.CC BY · PubMed Central
Fig. 4 CD8+ T-cell immune-checkpoint receptors and their ligands. Receptors stimulating CD8+ T-cell functions include CD28, ICOS and B7.1. Receptors mediating inhibitory signals include CTLA-4, PD-1 and B7.1. CD28 and CTLA-4 compete for the ligands B7.1 and B7.2 during the early stages of the CD8+ T-cell response. pMHC: peptide-loaded major histocompatibility complex, ICOS: inducible T-cell co-stimulator.
Fig. 4 CD8+ T-cell immune-checkpoint receptors and their ligands. Receptors stimulating CD8+ T-cell functions include CD28, ICOS and B7.1. Receptors mediating inhibitory signals include CTLA-4, PD-1 and B7.1. CD28 and CTLA-4 compete for the ligands B7.1 and B7.2 during the early stages of the CD8+ T-cell response. pMHC: peptide-loaded major histocompatibility complex, ICOS: inducible T-cell co-stimulator.CC BY · PubMed Central
Fig. 5 Development of chimaeric antigen receptors (CARs). The CAR construct comprises an antigen-binding scFv attached via a hinge to the CD3ζ signalling unit. Intracellularly, additional signalling units are attached to the CD3ζ chain. First-generation CARs contained only tyrosine-based activation motifs (ITAM) in the CD3 ζ-chain intracellular domain. Second-generation CARs include one co-stimulatory molecule, such as CD28 or 4-1BB, whereas third-generation CARs contain two co-stimulatory molecules, such as CD28 + 4-1BB (CD137). Fourth-generation CARs are based on second-generation CARs paired with a constitutively or inducibly expressed cytokine (e.g., IL-12) to further expand the T-cell population. Fifth-generation CARs are based on second-generation CARs with the addition of the intracellular domains of cytokine receptors (e.g., IL-2Rβ). CSM: co-stimulatory molecule, DCR: domain of cytokine receptors, IL-12: inducer activator of interleukin-12 transcription.
Fig. 5 Development of chimaeric antigen receptors (CARs). The CAR construct comprises an antigen-binding scFv attached via a hinge to the CD3ζ signalling unit. Intracellularly, additional signalling units are attached to the CD3ζ chain. First-generation CARs contained only tyrosine-based activation motifs (ITAM) in the CD3 ζ-chain intracellular domain. Second-generation CARs include one co-stimulatory molecule, such as CD28 or 4-1BB, whereas third-generation CARs contain two co-stimulatory molecules, such as CD28 + 4-1BB (CD137). Fourth-generation CARs are based on second-generation CARs paired with a constitutively or inducibly expressed cytokine (e.g., IL-12) to further expand the T-cell population. Fifth-generation CARs are based on second-generation CARs with the addition of the intracellular domains of cytokine receptors (e.g., IL-2Rβ). CSM: co-stimulatory molecule, DCR: domain of cytokine receptors, IL-12: inducer activator of interleukin-12 transcription.CC BY · PubMed Central
Fig. 6 CD8+ T-cell distribution within tumours. In solid cancers, tumours can be classified as hot, cold, altered–immunosuppressed or altered–excluded tumours based on the degree of tumour CD8+ T-cell infiltration and the composition of the tumour microenvironment (TME). Hot tumours are characterised by high infiltration of CD8+ T cells and respond better to immune-enhancing therapies, whereas cold tumours are less likely to benefit from such treatments. Cold tumours are characterised by the absence of CD8+ T-cell infiltration, while altered–immunosuppressed tumours have sparse CD8+ T-cell infiltration, localised in the tumour periphery, and the presence of myeloid-derived suppressor cells and regulatory CD8+ T cells in the tumour tissue. Altered–excluded tumours are dominated by an abnormal vasculature (and consequent hypoxia) and a dense stroma, while CD8+ T cells are located at the border of these tumours.
Fig. 6 CD8+ T-cell distribution within tumours. In solid cancers, tumours can be classified as hot, cold, altered–immunosuppressed or altered–excluded tumours based on the degree of tumour CD8+ T-cell infiltration and the composition of the tumour microenvironment (TME). Hot tumours are characterised by high infiltration of CD8+ T cells and respond better to immune-enhancing therapies, whereas cold tumours are less likely to benefit from such treatments. Cold tumours are characterised by the absence of CD8+ T-cell infiltration, while altered–immunosuppressed tumours have sparse CD8+ T-cell infiltration, localised in the tumour periphery, and the presence of myeloid-derived suppressor cells and regulatory CD8+ T cells in the tumour tissue. Altered–excluded tumours are dominated by an abnormal vasculature (and consequent hypoxia) and a dense stroma, while CD8+ T cells are located at the border of these tumours.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 106 references

Cited by

See all 1,687

Metadata

Authors
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I.
Affiliations
  • Zealand University Hospital Køge (DK)
  • University of Copenhagen (DK)
Corresponding author
Raskov, Hans
Venue
British Journal of Cancer
Published
2020-09-15
Volume
124
Issue
2
Pages
359-367
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W3087683890
Cited by
1,687
References
106
Citations by year
2026: 265 · 2025: 400 · 2024: 451 · 2023: 316 · 2022: 204 · 2021: 49 · 2020: 2
FWCI
16.07
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD8+ T cells, cytotoxic T lymphocytes, cancer immunotherapy, immune checkpoint inhibitors, chimeric antigen receptor, adoptive cell transfer, innate-adaptive immune interaction, antitumor immunity, combination therapy
MeSH terms
Animals, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Cytotoxic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41416-020-01048-4
The paper
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021). Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer. https://doi.org/10.1038/s41416-020-01048-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.